Operating income remains constrained with a 2.0% margin in 2026Q1, despite gross margins reaching 69.9%, indicating that SG&A expenses continue to outpace revenue growth.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 |
|---|
| Sales/Revenue | 107.34M | 109.43M | 92.13M | 71.52M | 62.45M | 61.29M | 43.31M | 24.6M | 21.21M | 12.13M | 7.75M | 7.22M | 6.5M | 4.96M | 2.05M | 1.11M | 71.06K | 26.72K | 83.69K | 100.32K |
| Revenue Growth % | 13.76% | 18.78% | 28.81% | 14.53% | 1.89% | 41.51% | 76.08% | 15.99% | 74.86% | 56.45% | 7.35% | 11.04% | 31.19% | 141.96% | 84.32% | 1464.09% | 165.93% | -68.07% | -16.58% | - |
| Cost of Goods Sold | 33.23M | 40.16M | 32.75M | 28.62M | 23.48M | 25.65M | 19.21M | 9.16M | 9M | 6.17M | 3.41M | 3.62M | 3.22M | 1.77M | 115.36K | 0 | 0 | 2.65M | 0 | 0 |
| COGS % of Revenue | - | 36.7% | 35.55% | 40.02% | 37.6% | 41.86% | 44.35% | 37.23% | 42.44% | 50.91% | 44.01% | 50.16% | 49.54% | 35.66% | 5.63% | - | - | 9905.55% | - | - |
| Gross Profit | 74.12M | 69.27M | 59.38M | 42.9M | 38.97M | 35.64M | 24.11M | 15.44M | 12.21M | 5.95M | 4.34M | 3.6M | 3.28M | 3.19M | 1.93M | 1.11M | 71.06K | -2.62M | 83.69K | 100.32K |
| Gross Margin % | 69.05% | 63.3% | 64.45% | 59.98% | 62.4% | 58.14% | 55.65% | 62.77% | 57.56% | 49.09% | 55.99% | 49.84% | 50.46% | 64.34% | 94.37% | 100% | 100% | -9805.55% | 100% | 100% |
| Gross Profit Growth % | - | 16.66% | 38.41% | 10.09% | 9.34% | 47.84% | 56.13% | 26.48% | 105.06% | 37.16% | 20.61% | 9.66% | 2.88% | 64.98% | 73.94% | 1464.09% | 102.71% | -3231.15% | -16.58% | - |
| Operating Expenses | 59.55M | 57.21M | 73.08M | 69.3M | 51.26M | 35.28M | 26.24M | 19.13M | 12.03M | 8.08M | 5.87M | 4.2M | 3.91M | 2.97M | 2.41M | 2.57M | 1.92M | 2.67M | 1.59M | 456.26K |
| OpEx % of Revenue | - | 52.28% | 79.33% | 96.9% | 82.08% | 57.56% | 60.58% | 77.78% | 56.71% | 66.65% | 75.75% | 58.11% | 60.09% | 60% | 117.78% | 230.81% | 2697.95% | 10005.55% | 1902.04% | 454.81% |
| Selling, General & Admin | 51.09M | 50.24M | 61.27M | 58.02M | 49.24M | 33.19M | 19.93M | 14.36M | 10.29M | 6.75M | 5.24M | 3.32M | 3.45M | 2.78M | 2.23M | 2.57M | 1.72M | 2.4M | 0 | 0 |
| SG&A % of Revenue | - | 45.92% | 66.5% | 81.12% | 78.84% | 54.15% | 46.02% | 58.4% | 48.54% | 55.65% | 67.57% | 46% | 53.11% | 56.08% | 108.65% | 230.81% | 2420% | 8965.77% | - | - |
| Research & Development | 3.48M | 0 | 0 | 0 | 0 | 0 | 0 | 1.6M | 675.66K | 1.01M | 398.4K | 290.37K | 189.57K | 130.29K | 126.92K | 0 | 78.44K | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | 6.52% | 3.19% | 8.32% | 5.14% | 4.02% | 2.92% | 2.63% | 6.2% | - | 110.37% | - | - | - |
| Other Operating Expenses | 4M | 6.96M | 11.82M | 11.28M | 2.02M | 2.09M | 6.31M | 3.16M | 449K | 324.55K | 235.28K | 583.95K | 264.34K | 193.97K | 187.1K | 0 | 119.08K | 277.86K | 1.59M | 456.26K |
| Operating Income | 14.57M | 12.06M | -13.71M | -26.4M | -12.29M | 361.1K | -2.14M | -3.69M | 180.13K | -2.13M | -1.58M | -597.41K | -1.03M | 215.6K | -364.35K | -1.45M | -1.85M | -2.65M | -1.51M | -355.94K |
| Operating Margin % | 13.57% | 11.02% | -14.88% | -36.91% | -19.68% | 0.59% | -4.93% | -15.02% | 0.85% | -17.56% | -20.4% | -8.27% | -15.78% | 4.35% | -17.78% | -130.81% | -2597.95% | -9905.55% | -1802.04% | -354.81% |
| Operating Income Growth % | - | 188% | 48.09% | -114.81% | -3503.69% | 116.91% | 42.19% | -2150.48% | 108.46% | -34.68% | -164.73% | 41.79% | -576.03% | 159.18% | 74.94% | 21.25% | 30.25% | -75.53% | -323.68% | - |
| EBITDA | 18.73M | 16.39M | -9.38M | -24M | -10.27M | 2.33M | -164.24K | -2.52M | 496.63K | -1.81M | -1.35M | -263.46K | -761.99K | 409.39K | -177.24K | -1.31M | -1.79M | -2.61M | -1.48M | -353.12K |
| EBITDA Margin % | 17.45% | 14.98% | -10.18% | -33.56% | -16.44% | 3.8% | -0.38% | -10.24% | 2.34% | -14.89% | -17.37% | -3.65% | -11.72% | 8.26% | -8.65% | -117.74% | -2513.62% | -9783.87% | -1763.62% | -352% |
| EBITDA Growth % | 391.05% | 274.77% | 60.93% | -133.72% | -541.39% | 1516.51% | 93.48% | -607.1% | 127.51% | -34.11% | -410.99% | 65.42% | -286.13% | 330.98% | 86.46% | 26.74% | 31.68% | -77.15% | -317.96% | - |
| D&A (Non-Cash Add-back) | 4.16M | 4.33M | 4.33M | 2.4M | 2.02M | 1.97M | 1.97M | 1.18M | 316.5K | 324.55K | 235.28K | 333.95K | 264.34K | 193.79K | 187.1K | 145.31K | 59.93K | 32.52K | 32.15K | 2.82K |
| EBIT | 14.63M | 12.06M | -13.22M | -23.71M | -11.44M | 361.1K | -1.32M | -2.69M | 787.8K | -2.13M | -1.54M | -595.14K | -1.03M | 215.85K | -454.45K | -1.16M | -1.9M | -4.55M | -4.25M | -355.94K |
| Net Interest Income | -4.81M | -4.94M | -5.83M | 738K | 852.3K | 16.98K | 68.58K | 288.03K | 46.21K | 25.94K | 42.31K | 2.27K | 935 | 246 | 369 | -957.35K | -103.71K | 29.16K | 4.48K | -5.53K |
| Interest Income | 342K | 353K | 329K | 2.19M | 852.3K | 16.98K | 68.58K | 288.03K | 46.21K | 25.94K | 42.31K | 2.27K | 935 | 246 | 469 | 1.29K | 2.84K | 30.19K | 5.09K | 0 |
| Interest Expense | 5.15M | 5.29M | 6.16M | 1.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 958.64K | 106.55K | 1.03K | 611 | 5.53K |
| Other Income/Expense | -4.98M | -5.11M | -5.68M | 1.24M | 852.3K | 16.98K | -71.81K | 1.45M | 46.21K | 25.94K | 42.31K | 2.27K | 935 | 246 | 369 | -666.78K | -162.79K | 738.43K | -2.74M | -5.53K |
| Pretax Income | 9.59M | 6.95M | -19.39M | -25.16M | -11.44M | 378.08K | -2.21M | -2.24M | 226.34K | -2.1M | -1.54M | -595.14K | -1.03M | 215.85K | -363.98K | -2.12M | -2.01M | -4.56M | -4.25M | -361.47K |
| Pretax Margin % | 8.93% | 6.35% | -21.04% | -35.18% | -18.32% | 0.62% | -5.1% | -9.13% | 1.07% | -17.35% | -19.86% | -8.24% | -15.77% | 4.35% | -17.77% | -190.8% | -2827.02% | -17047.82% | -5077.14% | -360.32% |
| Income Tax | 2.75M | 1.82M | 725K | -7.6M | 0 | 0 | 0 | 897.96K | 0 | 0 | 0 | 2.27K | 0 | 426 | 469 | 0 | 165.7K | 1.03K | 611 | 0 |
| Effective Tax Rate % | 28.71% | 26.16% | -3.74% | 30.19% | 0% | 0% | 0% | -40.01% | 0% | 0% | 0% | -0.38% | 0% | 0.2% | -0.13% | 0% | -8.25% | -0.02% | -0.01% | 0% |
| Net Income | 6.84M | 5.13M | -20.11M | -17.57M | -11.44M | 378.08K | -2.21M | -3.14M | 226.34K | -2.1M | -1.54M | -595.14K | -1.03M | 215.85K | -363.98K | -2.12M | -2.01M | -4.56M | -4.25M | -361.47K |
| Net Margin % | 6.37% | 4.69% | -21.83% | -24.56% | -18.32% | 0.62% | -5.1% | -12.78% | 1.07% | -17.35% | -19.86% | -8.24% | -15.77% | 4.35% | -17.77% | -190.8% | -2827.02% | -17047.82% | -5077.14% | -360.32% |
| Net Income Growth % | 144.36% | 125.52% | -14.48% | -53.57% | -3125.41% | 117.13% | 29.77% | -1488.41% | 110.76% | -36.7% | -158.63% | 41.96% | -575.06% | 159.3% | 82.84% | -5.56% | 55.9% | -7.22% | -1075.45% | - |
| Net Income (Continuing) | 6.84M | 5.13M | -20.11M | -17.57M | -11.44M | 378.08K | -2.21M | -3.14M | 226.34K | -2.1M | -1.54M | -595.14K | -1.03M | 215.85K | -454.55K | -2.12M | -2.01M | -4.56M | -4.25M | -361.47K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.36 | 0.27 | -1.10 | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 | 0.02 | -0.21 | -0.16 | -0.07 | -0.14 | -0.06 | -0.08 | -0.46 | -0.46 | -1.09 | -1.06 | -0.10 |
| EPS Growth % | 141.97% | 124.55% | -6.8% | -60.94% | -3090.65% | 114.27% | 34.78% | -1304.19% | 109.1% | -31.25% | -120.08% | 48.07% | -133.33% | 21.88% | 83.3% | 0% | 57.8% | -2.83% | -960% | - |
| EPS (Basic) | - | 0.28 | -1.10 | -1.03 | -0.64 | 0.02 | -0.15 | -0.23 | 0.02 | -0.21 | -0.16 | -0.07 | -0.14 | -0.06 | -0.08 | -0.46 | -0.46 | -1.09 | -1.06 | -0.10 |
| Diluted Shares Outstanding | 18.76M | 19M | 18.29M | 17.12M | 17.78M | 17.69M | 14.83M | 13.39M | 11.86M | 9.82M | 9.9M | 8.19M | 7.46M | 7.07M | 4.74M | 4.64M | 4.41M | 4.19M | 4M | 3.47M |
| Basic Shares Outstanding | 18.76M | 18.56M | 18.29M | 17.12M | 17.78M | 17.23M | 14.83M | 13.39M | 11.32M | 9.82M | 9.9M | 8.19M | 7.46M | 4.8M | 4.74M | 4.64M | 4.41M | 4.19M | 4M | 3.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue concentration and seasonality
As indicated by recent quarterly filings, OptimizeRx experienced a significant revenue contraction of 9.5% in 2026Q1, following a period of inconsistent growth that saw a 55.2% surge in 2025Q2, highlighting the inherent instability of its campaign-based business model and reliance on pharmaceutical marketing cycles.
The sharp fluctuations in top-line performance suggest that the company's transition toward recurring revenue models remains incomplete. Investors should monitor whether the recent decline reflects a structural shift in pharma spending or merely the expected volatility of a transactional, campaign-driven revenue base.
Based on reported financial data, gross margins have fluctuated between 60.9% and 74.8% over the last ten quarters, reflecting the impact of variable distribution fees paid to EHR partners which act as a persistent structural constraint on the company's overall profitability profile.
The variability in gross margins appears tied to the mix of messaging versus data-driven products. Unless the company can successfully shift its revenue composition toward higher-margin, proprietary data solutions, these distribution costs will likely continue to limit the scalability of the gross margin.
According to the income statement history, operating income has failed to scale consistently with gross profit, as evidenced by the 2026Q1 operating margin of 2.0% despite a gross margin of 69.9%, suggesting that SG&A expenses remain disproportionately high relative to the company's current revenue scale.
The persistent reliance on heavy SG&A spending to maintain EHR integrations and pharma relationships suggests that the business has not yet achieved meaningful operating leverage. This warrants further investigation into whether current sales and marketing investments are yielding the expected long-term customer lifetime value.
As reported in recent financial statements, the company frequently utilizes stock-based compensation, with figures reaching $2.9 million in 2024Q4, which significantly obscures the underlying cash-generating capability of the business and complicates the assessment of true GAAP profitability during periods of operational expansion.
The recurring use of equity-based incentives suggests that reported net income may not fully capture the economic cost of talent acquisition. Analysts should adjust for these non-cash charges to determine if the core business is truly capable of sustaining positive free cash flow without dilutive financing.
While management emphasizes a pivot toward data-driven engagement, the market's persistent valuation of the firm as a digital coupon provider, as seen in the historical income statement volatility, suggests a significant risk that the core business remains vulnerable to commoditization and EHR partner leverage.
Short-term revenue spikes may be masking a long-term trend of margin compression if major EHR providers demand higher take-rates. Investors should remain skeptical of the 'data-analytics' narrative until the company demonstrates a sustained decoupling of revenue growth from traditional, lower-margin transactional messaging programs.
Quick answers to the most common questions about buying OPRX stock.
For fiscal year 2025, OptimizeRx Corporation (OPRX) reported total revenue of $109.4M. This represents a 108982.1% increase compared to $0.1M in 2007.
OptimizeRx Corporation (OPRX) is profitable, generating $5.1M in net income for the fiscal year ending 2025 with a net profit margin of 4.7%.
OptimizeRx Corporation (OPRX) reported an operating income of $12.1M, resulting in an operating profit margin of 11.0%. This margin reflects the operational efficiency of the business before interest and taxes.
OptimizeRx Corporation (OPRX) generated $69.3M in gross profit for the year, representing a gross profit margin of 63.3%. This demonstrates the company's core pricing power and production efficiency.